Cisplatin in Translational Oncology: Mechanisms, Models, and
2026-04-24
This thought-leadership article explores the mechanistic and strategic role of Cisplatin (CDDP) in translational cancer research. Integrating current insights into DNA crosslinking, apoptosis induction, and chemoresistance, it bridges mechanistic findings with actionable guidance for experimental design in cell viability and tumor xenograft models. Drawing on recent evidence and protocol recommendations, the piece highlights APExBIO’s Cisplatin (SKU A8321) as a benchmark reagent and proposes outlooks for overcoming resistance and maximizing translational impact.
Topotecan vs. Carboplatin Regimens in Ovarian Cancer: Eviden
2026-04-23
A Cochrane systematic review evaluated the efficacy of topotecan addition to standard carboplatin/paclitaxel regimens in ovarian cancer. The analysis provides rigorous comparative survival and progression metrics, informing ongoing optimization of platinum-based DNA synthesis inhibitor strategies in preclinical and translational oncology.
Practical Guide: 2-NBDG Glucose Uptake Assay Kit (K2212)
2026-04-23
The 2-NBDG Glucose Uptake Assay Kit offers a non-radioactive, fluorescence-based method for quantifying glucose uptake at the single-cell level, avoiding the hazards of traditional radioactive tracers. This kit is best suited for cellular studies of glucose metabolism, including applications in cancer and diabetes research, but should not replace in vivo or in situ tissue imaging where different validation standards may be required.
Technical Guide: Angiotensin I/II (1-5) in RAS Assays
2026-04-22
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled modeling of the renin-angiotensin system (RAS) in cardiovascular and renal research. It is intended for workflows investigating blood pressure regulation and aldosterone signaling, and should not be used in unrelated peptide or signaling studies.
QPRT Enhances Breast Cancer Invasiveness via PLC-Dependent P
2026-04-22
Liu et al. identify quinolinate phosphoribosyltransferase (QPRT) as a driver of breast cancer invasiveness through myosin light chain phosphorylation, implicating purinergic and phospholipase C (PLC) signaling. Their mechanistic work highlights PLC inhibition as a potential strategy for modulating cancer cell migration and offers translational insight into NAD+ metabolism in tumor progression.
2-Deoxy-D-glucose: Precision Glycolysis Inhibition in Resear
2026-04-21
2-Deoxy-D-glucose (2-DG) from APExBIO empowers researchers to dissect metabolic and immunological pathways with rigor and reproducibility. This guide details applied protocols, experimental troubleshooting, and cross-domain insights, enabling breakthrough findings in cancer, virology, and immunometabolism.
G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Research
2026-04-21
G-1 is a potent and selective GPR30 agonist enabling targeted modulation of non-genomic estrogen signaling. It demonstrates high specificity, strong in vitro and in vivo efficacy, and is a valuable tool for cardiovascular and breast cancer research. APExBIO provides validated workflow support for G-1, ensuring reproducible results in cell and animal models.
Clozapine in Prefrontal Cortex Signaling: A New Research Fro
2026-04-20
Explore how Clozapine, a leading atypical antipsychotic medication, uniquely modulates prefrontal cortical signaling and ERK1/2 pathways in advanced schizophrenia research. This article delivers original insights into experimental design and translational implications, distinguishing itself with a deep dive into molecular mechanisms and recent breakthroughs.
Repurposing Natural Compounds: Molecular Docking Against SAR
2026-04-20
This study systematically evaluates natural vitamins as inhibitors of the SARS-CoV-2 main protease (3CLpro) and spike RBD using in silico screening and molecular dynamics. The findings highlight specific compounds with strong binding affinities at key viral sites, offering a technical foundation for antiviral therapeutics research targeting coronavirus entry and replication.
Cefazedone (Refosporen): In Vitro Protocols and Troubleshoot
2026-04-19
Cefazedone (Refosporen) empowers researchers with robust, reproducible protocols for antibacterial testing across Gram-positive and Gram-negative strains. This article distills validated workflows, troubleshooting insights, and new chromatographic innovations for optimal laboratory and translational outcomes.
S-Adenosylmethionine (SAM): Systems Biology & Therapeutic In
2026-04-18
Explore how S-adenosylmethionine (Ademetionine) orchestrates methylation reactions and neural signaling at a systems level. This article uniquely integrates multi-omic mechanisms with translational research, offering advanced guidance for assay design and central nervous system disorder studies.
Biotin-tyramide: Technical Guide for TSA Signal Amplificatio
2026-04-17
Biotin-tyramide enables robust enzyme-mediated signal amplification in immunohistochemistry (IHC) and in situ hybridization (ISH), addressing the need for high-sensitivity detection of low-abundance targets. This technical article details its use, parameters, workflow integration, and limitations, supporting researchers optimizing TSA protocols. It is not intended for diagnostic or clinical applications.
Hyperthermia Enhances PARP Inhibitor Sensitivity in BRCA2+ O
2026-04-16
This study demonstrates that hyperthermia-induced reduction of BRCA2 protein sensitizes BRCA2-proficient ovarian carcinoma cells to PARP inhibition. The findings suggest a novel combinatorial strategy for overcoming resistance to PARP inhibitors in ovarian cancer, with significant implications for translational cancer research.
Ionisable Lipid Variations Drive LNP Efficacy for mRNA Deliv
2026-04-15
This study systematically evaluates how structural differences in ionisable lipids and sterol components shape the physicochemical properties, biodistribution, and expression efficacy of lipid nanoparticle (LNP) systems delivering mRNA. The findings provide actionable insights for optimizing LNP-based mRNA therapeutics and highlight important disparities between in vitro and in vivo performance.
Advancing In Vitro Drug Response Metrics in Cancer Research
2026-04-14
Schwartz’s dissertation critically evaluates current in vitro methods for assessing anticancer drug responses, distinguishing between relative and fractional viability as distinct yet often conflated metrics. The work reveals nuanced drug effects on both proliferation and cell death, providing actionable insights for experimental design and interpretation.
459 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page